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METHODOLOGY Open Access
Improved negative selection protocol for
Plasmodium berghei in the rodent malarial model
Rachael Y Orr, Nisha Philip and Andrew P Waters*
Abstract
An improved methodology is presented here for transgenic Plasmodium berghei lines that express the negative
selectable marker yFCU (a bifunctional protein that combines yeast cytosine deaminase and uridyl phosphoribosyl
transferase (UPRT)) and substitutes delivery of selection drug 5-fluorocytosine (5FC) by intraperitoneal injection for
administration via the drinking water of the mice. The improved methodology is shown to be as effective, less
labour-intensive, reduces animal handling and animal numbers required for successful selection thereby
contributing to two of the “three Rs” of animal experimentation, namely refinement and reduction.
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Background
Reverse genetics in malaria parasites has been possible
since the early to mid-90s [1-3] and it is now established
for a number of Plasmodium species that infect a variety
of hosts including human (Plasmodium falciparum),
rodent (Plasmodium berghei, Plasmodium yoelii [4] and
Plasmodium chabaudi [5]) primate (Plasmodium know-
lesi and Plasmodium cynomolgi) as well as avian (Plas-
modium gallinaceum). Typically genetically transformed
parasites are positively selected in the proliferating asex-
ual blood stages by their expression of a marker protein
that confers resistance to a common antibiotic and in
some cases specifically an anti-malarial drug. The num-
ber of selectable markers available for positive selection
is limited, where currently five are available for use with
parasites that can be cultured in vitro for long periods
(i.e. P. falciparum, P. knowlesi and P. cynomolgi). How-
ever, selection in rodent malaria parasites may only be
carried out in vivo as they cannot be cultured long term
in vitro, reducing the number of positive selectable mar-
kers available to three: Toxoplasma DHFR-thymidylate
synthase (tgDHFR-TS) and P. berghei DHFR-thymidylate
synthase (pbDHFR-TS), which impart resistance to pyri-
methamine and, human dihydrofolate reductase
(hDHFR) which confers resistance to both pyrimetha-
mine and WR99210. Therefore, there are only two
positive selection regimes available when working with
the rodent malarial model since both Apicomplexa pos-
sess genes producing DHFR-TS which confers resistance
to the same anti-malarial drug, pyrimethamine.
Although sequential genetic modification on P. berghei
using these markers in the strict order of DHFR-TS
selection with pyrimethamine followed by hDHFR selec-
tion with WR99210 [6] is possible, the number of
manipulations is still limited to two. Therefore, an alter-
native strategy was developed using a negative selection
procedure to recycle the both the positive and negative
selectable markers, which could then be used multiple
times on the same parasite line [7].
Negative selection in reverse genetics typically selects
for the loss of a marker in the presence of a suicide sub-
strate that is metabolized by the marker to create a sub-
stance that is toxic within the cell under selection.
Thymidine kinase is the most well used negative select-
able marker and metabolizes either ganciclovir (to gan-
ciclovir triphosphate) or acyclovir (to acyclo-guanosine
monophosphate - acyclo-GMP) which compete with
GTP for incorporation into DNA resulting in termina-
tion of elongation which is lethal to the cell.
An alternative negative selectable marker that has
been shown to work well in malaria parasites is a
bifunctional protein (yFCU) [7,8] that combines yeast
cytosine deaminase and uridyl phosphoribosyl transfer-
ase (UPRT): yFCU confers sensitivity to the drug 5-
fluorocytosine (5FC) which is metabolized to generate 5’
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fluorocytosine triphosphate (5FCTP), a lethal analogue
of CTP. Therefore, it is possible with a transgenic P.
berghei line that expresses yFCU to recycle the limited
number of positive selectable markers via negative selec-
tion and homologous recombination (see Figure 1). The
resulting drug sensitive parasite line lacking selectable
marker genes may then be genetically manipulated a
second time. This recycling event of the selectable mar-
ker can be exploited for use on multiple occasions,
enabling introduction of transgenes that complement
the loss of gene function in knock-outs as confirmation
of phenotype.
The procedure that was previously developed for
negative selection using 5FC required the administration
IP of 1 g/kg 5FC once each day for four days. A typical
selection procedure will use five mice and the parasite
population that survives generally contains a mixture of
parasites that have been genuinely selected and lack the
negative selectable marker and parental parasites that
have been unaffected by the selection process. Pre-
viously, Braks et al demonstrated those unaffected by
the selection process were due to either no longer pos-
sessing the yfcu gene anymore or the entire locus being
restored. The post-selection populations are then moni-
tored by PCR or Southern blot analysis to determine the
ratio of parental to recombined and the population with
the most advantageous ratio is used for cloning by limit-
ing dilution. A total of 16 mice are used for this process
and under some European regulations mice receiving IP
injections must be subjected to light anaesthesia. Of this
16, the negative selection requires five mice. Regulations
are being tightened in many countries resulting in new
techniques being investigated to reduce animal numbers
(personal communications), until these are established
the refinement of existing techniques is the only route
to conform to governing bodies specifications.
A protocol is reported here that permits the negative
selection of P. berghei parasites expressing yFCU
through the administration of 5FC via the drinking
water of the animals, thereby obviating the need for
injections and anaesthesia. The drug need only be chan-
ged after four days reducing labour and the selected
populations are sufficiently pure to allow subsequent
cloning permitting the use of only two mice for the
initial selection, reducing animal use by one and a half
fold. This refinement to the administration of selection
drugs has been seen before with pyrimethamine. [9]
Methods
Animals and reagents
TO (Theiler’s original) or NIH Swiss outbred mouse,
female, 20-30 g, aged 6 weeks. 5FC (5-fluorocytosine)
(Sigma-Aldrich): 0.5 mg/ml and 1.5 mg/ml in drinking
water. All animal procedures were carried out according
to Home Office regulations and protocols were
approved by the University of Glasgow Ethics Commit-
tee. Animals were infected by IP injection with 0.1 ml of
a thawed suspension of cryopreserved infected erythro-
cytes or via passage intraperitoneally.
Negative selection was carried out following either the
protocol outlined here using administration of 5FC in
drinking water or it was performed according to pre-
viously published procedures [7], which is available at
the Leiden Malaria Research Group Sharepoint site [9].
Protocol
This protocol is based upon the use of outbred mice
weighing 20-30 g, presuming that the animal consumes,
as was observed, 5-10 mls of drinking water daily, to
receive an equivalent dose of 80-750 mg/kg/day of 5FC.
In a recent human study, 100 mg/kg/day orally was
found to be safe over a course of two weeks this was
used as a basis for the lower dose [10]. The existing IP
delivery method using 1 g/kg/day was considered as a
guide for the higher dose in this experiment. Before
commencing this study, other drug qualities were noted
such as, the half-life which is shown as 3-5 hours before
excretion in the urine of a healthy individual [11] and
the bioavailability is 76-89% [12]. Previously negative
selection was carried out over four days during which
10 mg of 5FC was intraperitoneally injected every day.
The 5FC stock was supposed to be at 20 mg/ml in 0.9%
NaCl solution, a concentration found past the limit of
solubility of the compound, therefore, 1 ml of 10 mg/ml
was used. However, as in water it was possible to
achieve a 15 mg/ml concentration of 5FC, bulk solutions
of lower concentration to be used for administration in
drinking water could be easily prepared.
The reporter line 820cl1m1cl1 [RMgm-164] (standard
nomenclature used in this field is ‘cl’ for clone and ‘m’
for mouse indicating the line has undergone negative
selection) was created for sex specific expression of
fluorescent markers, rfp is female specific expression
driven by the lccl promoter and male specific egfp is dri-
ven by the heavy dynein chain promoter [13]. For these
studies, the parental stock 820cl1 of this reporter line
prior to negative selection was used to compare delivery
methods. A TO or NIH Swiss outbred mouse weighing
25 g was infected by IP injection on day 0, typically a
Friday, with 0.1 ml of a thawed suspension of cryopre-
served 820cl1 frozen at a parasitaemia of 3-5% infected
erythrocytes. Giemsa-stained thin blood films were
observed daily to monitor the parasitaemia. Upon reach-
ing 0.5-3% parasitaemia, a passage was performed into
four mice. It has been established locally and deter-
mined empirically that an IP injection of 50 μl of car-
diac blood at 0.2-1% parasitaemia mixed with 0.2 mls of
PBS produces a parasitaemia of 0.2-1.5% after 48 hours,
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Figure 1 Negative selection with 5 fluorocytosine a comparison of IP with newly refined oral delivery. A. Integration locus 230p with
plasmid pL1186. B. Integration locus 230p post negative selection. C. Southern analysis of negative selection restriction digest. D. PCR of full
selection cassette. E. PCR of selectable marker yFCU. F. Primer details. Negative selection with 5 fluorocytosine (5FC) via IP 10 mg/day over 4
days (820cl1m1-m4) and drinking water at 0.5 mg/ml (820cl1m1d-m2d) and 1.5 mg/ml (820cl1m3d-4d) (A) Schematic representation of
integration locus 230p of pL1186 used to create the 820cl1 line at pb230p region after positive selection of the double crossover integration
event with pyrimethamine, restriction digest with NcoI-PstI creates 3.3 kb and 1.1 kb fragments in Southern analysis shown here with thin black
arrows (see C). The bold boxes indicate the region of the only feasible recombination event (3’pbdhfr/ts) through negative selection. Bold dotted
arrows display the primers 1 & 2 used in diagnostic PCRs to amplify the whole cassette at 3.9 kb (see D & F) and 3 & 4 to amplify yFCU the
selectable marker for negative selection of recombinants at 0.9 kb (see E & F). (B) Schematic of gene locus after negative selection with 5
Fluorocytosine (5FC), box in bold represents the footprint left from recombination event after negative selection. Restriciton digest with NcoI-PstI
results in 1.6 kb band shown by thin arrows. Bold dotted arrows show expected PCR fragment with primers 1 & 2 producing a 1.1 kb band (see
F). (C) Southern blot analysis of restriction digest on 10 μg of genomic DNA and 5 ng of plasmid pL1186 with NcoI and PstI using 3’pbdhrf/ts as
a hybridisation probe (bold boxes in Figure 1A and B). Expected band size for negatively selected is 1.6 kb (820cl1m1, 820cl1m1d, 820cl1m1dcl2
and G260cl1) and pre-negative selection is 3.3 kb (820cl1 and pL1186) and 1.1 kb (820cl1). (D) PCR of full selection cassette with primers 1 & 2
(see 1E) to amplify a region of 3.9 kb before selection (820cl1) and 1.1 kb after selection (820cl1m1-4 and 8320cl1m1d-4d) negative control is HP
wt with no band. (E) PCR of yFCU negative selectable marker with primers 3 & 4 (see 1E), band of 0.9 kb shows that yFCU is present. Positive
control is 820cl1 and pL1186, negative control is HP wt lacking selectable markers. (F) Detailed information of primers used in this study.
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typically a Wednesday. Five hundred microlitres of car-
diac blood at parasitaemia 0.5-5%, administered IP
would result in the desired infection levels in 24 hours
to proceed with negative selection treatment.
The pro-drug 5FC was prepared to concentrations of
0.5 mg/ml and 1.5 mg/ml using vigorous shaking to dis-
solve the crystals. This drug can be further encouraged
into solution by using pre-warmed tap water and a vor-
tex. Drinking water with 5FC was applied in opaque or
darkened bottles, as the drug is light sensitive, at a para-
sitaemia of ≥ 0.1%. The infection levels dropped to zero
after 48 hours, in both the 0.5 mg/ml (m1d - 2d) and
1.5 mg/ml (m3d - 4d) dosage sets. Parasites were
detected again 48 hours post clearance and, the mice
were sacrificed at ≥ 3% parasitaemia to harvest blood
for cryopreservation and preparation of leucocyte and
erythrocyte free pellets. The drugged water was renewed
after 4 days. Once selection was established in the
drinking water sets, 820cl1m1d was chosen to produce a
clonal line named 820cl1m1dcl2. This positive/negative
selectable marker free line was tested for further genetic
manipulation by deleting the PBANKA_120440 gene
(G260cl1) using a DXO vector pL0035 [7,9]which con-
tains positive and negative selectable markers. The pel-
lets recovered from all the above-mentioned lines were
then processed for genomic DNA extraction to perform
comparative diagnostic PCRs and Southern analyses
alongside the untreated control (820cl1).
Genotype analysis of parasites post negative selection
Diagnostic PCRs and Southern analysis of restriction
digests were performed according to standard methods
on the IP control group, the drinking water group, the
original 820cl1 pre-negative selection parasite stock and
the pL1186 construct used to create 820cl1 [13] (Figure
1). Recombination of the 3’pbdhfr-ts homology regions
removing the selectable cassette hence verifying that
negative selection occurred was demonstrated by PCR
amplification of 30 cycles with the external primer pair
GU0595 CCgggcccATGACATCATTTATAAATCATG
and GU0918 GTAAAGGGTTAATTCTTATATGGTCG.
Further evidence of removal of the selection cassette
was confirmed by PCR using primers GU1133 GTGA-
CAGGGGGAATG and GU1134 GATAGCACTAC-
CACCGG to amplify the yfcu selectable marker.
Southern analysis was completed on genomic DNA of
one member from each group, an IP control (820cl1m1),
drinking water (820cl1m1d), cloned after selection using
drinking water (820cl1m1dcl2), and a line to demonstrate
positive selection of a second transfection on the
820cl1m1dcl2 background (G260cl1) and plasmid DNA
pL1186. Ten micrograms of DNA was digested with NcoI
and PstI [13] overnight at 37°C and subsequently loaded
onto a 1.2% agarose gel stained with Sybr safe. The
resulting blot was then hybridized with the 3’pbdhfr-ts
probe amplified from pL1186 DNA template with primer
pair LUMC692 CTTATATATTTATACCAATTG and
LUMC693 GTTTTTTTTTAATTTTTCAAC.
Results
Refinement to negative selection of recombinant
parasites in vivo
Negative selection pressure on mutant parasites with a
disrupted gene using oral administration of the pro-drug
5FC was verified to be as efficient as the existing
method applied intraperitoneally. The predicted homo-
logous recombination event (Figure 1A/B) resulting
from effective negative selection is evident by Southern
analysis (Figure 1C) with only the original 820cl1 line
(3.3 kb and 1.1 kb) and pL1186 plasmid (3.3 kb) show-
ing any presence of the selection cassette (Figure 1A/B).
The negatively selected 820cl1m1, 820cl1m1d and
G260cl1 all display the 1.6 kb band expected after
homologous recombination of 3’pbdhfr/ts demonstrating
that this line is amenable to additional manipulations
subsequent to the selection process. The parasite line
G260cl1 was created through transfection of
820cl1m1dcl2 with a PBANKA_120440 KO construct
introducing the pL0035 plasmid which possesses both
positive and negative selectable markers, resulting in a
line that was positively selected for a second time and
subsequently cloned.
More sensitive diagnostic PCRs with 60 ng of DNA
per reaction as standard was quantified by NanoDrop
1000 from Thermo Scientific (DNA can be quantified
spectrophotometrically by other means) have shown
that the selection cassette is only present in 820cl1
parasite line at 3.9 kb whilst in all of the standard IP
control group (m1 - 4) and orally administered mice
(m1d & 2d on 0.5 mg/ml 5FC and m3d & 4d on 1.5
mg/ml 5FC) the presence of a smaller 1.1. kb band
confirms the absence of the selection cassette (Figure
1D). To supplement this finding, additional PCRs were
carried out on sub-sections of the cassette, all of which
given the non-quantitative nature of PCR were present
at apparently well-reduced levels in both the IP control
group and oral group in comparison with the
untreated 820cl1 line. Further cloning by serial limiting
dilutions resulted in a pure population without the
selection cassette yielding the 820cl1m1dcl2 line.
Levels of the yfcu PCR product varied greatly amongst
the IP control group from almost zero in 820cl1m1 to
as much as was observed in the selection cassette posi-
tive line 820cl1 in 820cl1m3. Conversely the drinking
water group consistently had lower levels of yfcu than
820cl1. As expected, the oral group apparently
responded in a dose dependent manner with
820cl1m3d and 820cl1m4d, which were on the higher
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dose of 1.5 mg/ml had less yfcu present than the
820cl1m1d and 820cl1m2d 0.5 mg/ml pair (Figure 1E).
Discussion
Evidence suggests that the adapted method of orally admi-
nistered 5FC for negative selection is just as effective as
the existing IP method currently utilized. Furthermore, the
modified technique has the additional benefits of reducing
animal numbers required and refining their treatment by
removing the need for injectables in this protocol. More-
over there are financial gains made by reduction in cost
for the animals, their housing, consumables, drug, and
labour. The procedure may be carried out in the UK by
personnel who do not possess a personal Home Office
animal license, although an amended list of designated
duties is added to the laboratory license. Regional policies
may differ. A comparison between two doses for oral
administration was drawn in this experiment with the
same successful end result (Figure 1D). Currently we use 1
mg/ml 5FC, which sits between the two doses of 0.5 mg/
ml and 1.5 mg/ml. It would be recommended that if no
reduction in parasitaemia is observed after 24 hours that
the dose can be increased to 1.5 mg/ml to ensure full
clearance of parasites. A mouse from the lower dose
(820cl1m1d) was chosen to clone (820cl1m1dcl2) demon-
strating that even at lower doses this method is reliable. It
has been observed since on each occasion negative selec-
tion using doses ranging between 0.5 to 1.5 mg/ml in
drinking water that a homologous recombination event
has been successful in every mouse.
The method above describes using five mice in total for
selection, one as a donor to propagate the parasites for
passage and four to carry out the negative selection. The
protocol has been modified further with personal obser-
vations that by using two mice instead of four for the
selection, they can be infected with 50 μl from one cryo-
preserved stabilate on day 0 removing the need for three
mice. The recombined product validating successful
negative selection has been achieved on every occasion.
This would mean that in comparison to the previous
method a negative selection and cloning procedure could
be concluded with as little as 13 mice. In all experiments
where negative selection pressure has been administered
through drinking water-based delivery of 5FC it was pos-
sible to clone parasite lines by limiting dilution that had
undergone the anticipated recombination event. No false
positive lines were generated indicating that oral admin-
istration of 5FC produces sufficiently pure recombined
populations of parasites for further use.
Conclusion
The modified negative selection method described here
is shown to work successfully at a range of doses with-
out bringing harm to the animal. This protocol fulfils
two of the “three R’s”, refinement and reduction appeas-
ing the requirements of governing bodies monitoring
animal usage. Moreover it reduces the animal numbers
required hence cutting housing, reagents, consumables,
and labour costs as well as time to produce reliable and
consistent results that are easily achieved. In principle
this approach is applicable to transfection studies with
all rodent malaria parasite models.
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